Research area · Copper-peptide research

Copper-peptide research, topical and beyond.

GHK-Cu is a copper-binding tripeptide first isolated from human plasma in 1973. Small topical studies in people have looked at skin appearance; data on the injected form is scarce.

  • Evidence grade or review status for every compound
  • Sources listed on every page
  • US and sport status, dated
1 compoundEarly human (topical)
Updated Nov 2026Dated on every page
GHK-CU
The research so far

What has been studied

GHK was isolated from human plasma in 1973; its copper complex was characterised later. [1]

Small topical studies in people have looked at skin appearance. We found no controlled trial of injected GHK-Cu, published or registered, when we checked PubMed and ClinicalTrials.gov in November 2026. [1] [3]

The FDA says compounded injectable GHK-Cu may carry a risk of immune reactions, because of possible aggregation and peptide-related impurities, and that there are limited data in humans to inform its safety. [2]

Evidence grades

How far the research has gone

Pick a compound to see the highest rung reached, from cell study to approval.

Cell studies
—
Animal studies
—
Human pilot / case series
—
Controlled human trials
—
Regulatory approval
—
Highest rung reached
—

How we grade evidence

What the research does not show

Saying what we don't know is part of the evidence.

Any effect of injected GHK-Cu in people from a controlled trial.

Results for any person: the topical studies measured skin outcomes in small groups.

Where it stands legally

As of November 2026. See the full tracker and the changelog.

CompoundFDA approval503A compounding (2026)WADA (2026 List)
GHK-CuNot approvedInjectable form formerly FDA Category 2; nomination withdrawn (FDA list, current 22 Apr 2026); not in the July reviewNot named; S0 covers unapproved substances

Worth knowing

Research use only

None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.

What research use only means

No doses, ever

We publish no doses, protocols, or cycles for people, on any page.

Why we publish no doses

How we grade evidence

Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.

Evidence grades

Questions people ask

Is topical GHK-Cu different from injected GHK-Cu?

Yes, in the evidence. Small topical studies in people have looked at skin appearance; we found no controlled trial of the injected form.

Why is GHK-Cu blue?

The copper in the complex gives it its colour. Colour is not proof of identity: a lab report should confirm identity by mass.

Sources

  1. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID 29986520. pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  2. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  3. PubMed (clinical-trial filters) and ClinicalTrials.gov searches for controlled trials of injected GHK-Cu (terms GHK-Cu, Cu-GHK, GHK Cu, copper tripeptide-1, prezatide), 18 November 2026: none found. clinicaltrials.gov/search?term=GHK-Cu
  4. World Anti-Doping Agency. Prohibited List 2026 (in force 1 January 2026) and 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list

Start with the evidence

Every page sourced and dated, including what the research does not show.

Open the research library
Written by 6AM Research. Drafted with AI from published studies, trial registries, and regulator documents, plus press reports where marked. Every page lists its sources and is dated. Editorial policy · Corrections
Education only. Nothing here is medical advice or describes use in people. Research use only